Intestine-derived sorbitol drives steatotic liver disease in the absence of gut bacteria

Sci Signal. 2025 Oct 28;18(910):eadt3549. doi: 10.1126/scisignal.adt3549. Epub 2025 Oct 28.

Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD) is linked to a shift in the composition of the gut microbiome. Here, we found that depletion of the gut microbiome in adult zebrafish led to the development of steatotic liver disease in animals on standard diets. Using metabolomics and isotope tracing, we found that dietary glucose was converted to sorbitol by host intestinal cells. Although bacteria degraded sorbitol in control animals, sorbitol was transferred to the livers of fish when the gut microbiome had been depleted. Within the liver, sorbitol was converted into fructose 1-phosphate, which subsequently activated glucokinase and increased glycolytic flux, leading to increased hepatic glycogen and fat content. Inhibition of sorbitol production in microbiome-depleted animals was sufficient to prevent the development of steatotic liver, and colonizing the intestines of microbiome-depleted fish with sorbitol-degrading Aeromonas bacterial strains rescued the steatotic liver phenotype. Conversely, exogenous administration of high concentrations of sorbitol phenocopied gut microbiota depletion and induced hepatic steatosis. Together, these findings show that sorbitol-degrading bacteria in the gut protect against steatotic liver disease and suggest that excessive intake of dietary sorbitol may pose a risk for the development of MASLD.

MeSH terms

  • Animals
  • Fatty Liver* / etiology
  • Fatty Liver* / metabolism
  • Gastrointestinal Microbiome*
  • Rhodanine / analogs & derivatives
  • Sorbitol* / adverse effects
  • Sorbitol* / metabolism
  • Thiazolidines
  • Zebrafish

Substances

  • Sorbitol
  • epalrestat
  • Rhodanine
  • Thiazolidines